HUSCAP logo Hokkaido Univ. logo

Hokkaido University Collection of Scholarly and Academic Papers >
医学研究院・医学院  >
雑誌発表論文等  >

Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel

この資料はクリエイティブ・コモンズ・ライセンスの下で公開されています。

フルテキスト
ol_12_6_4493_PDF.pdf1.35 MBPDF見る/開く
この文献へのリンクには次のURLを使用してください:http://hdl.handle.net/2115/64709

タイトル: Time-dependent transition of the immunoglobulin G subclass and immunoglobulin E response in cancer patients vaccinated with cholesteryl pullulan-melanoma antigen gene-A4 nanogel
著者: Kyogoku, Noriaki 著作を一覧する
Ikeda, Hiroaki 著作を一覧する
Tsuchikawa, Takahiro 著作を一覧する
Abiko, Takehiro 著作を一覧する
Fujiwara, Aki 著作を一覧する
Maki, Takehiro 著作を一覧する
Yamamura, Yoshiyuki 著作を一覧する
Ichinokawa, Masaomi 著作を一覧する
Tanaka, Kimitaka 著作を一覧する
Imai, Naoko 著作を一覧する
Miyahara, Yoshihiro 著作を一覧する
Kageyama, Shinichi 著作を一覧する
Shiku, Hiroshi 著作を一覧する
Hirano, Satoshi 著作を一覧する
キーワード: immunoglobulin E
MAGE-A4
vaccine
antibody response
immunoglobulin G subclass
発行日: 2016年12月
出版者: Spandidos Publications
誌名: Oncology Letters
巻: 12
号: 6
開始ページ: 4493
終了ページ: 4504
出版社 DOI: 10.3892/ol.2016.5253
抄録: A phase I+II clinical trial of vaccination with MAGE-A4 protein complexed with cholesteryl pullulan melanoma antigen gene-A4 nanogel (CHP-MAGE-A4) is currently underway in patients with MAGE-A4-expressing cancer. In the present study, the primary phase I endpoint was to test the safety of the administration of 300 μg CHP-MAGE-A4 with and without OK-432. Another aim of the study was to clarify the details of the specific humoral immune response to vaccination. The 9 patients enrolled for phase I were vaccinated 6 times, once every 2 weeks: 3 patients with 100 μg and 3 patients with 300 μg CHP-MAGE-A4, and 3 patients with 300 μg CHP-MAGE-A4 plus 0.5 clinical units of OK-432. Toxicities were assessed using Common Terminology Criteria for Adverse Events v3.0. Clinical response was evaluated by modified Response Evaluation Criteria in Solid Tumours. Immunological monitoring of anti-MAGE-A4-specific antibodies was performed by ELISA of pre- and post-vaccination patient sera. The 6 vaccinations produced no severe adverse events. Stable disease was assessed in 4/9 patients. Anti-MAGE-A4 total immunoglobulin (Ig)G titers increased in 7/9 patients. Efficacious anti-MAGE-A4 IgG1, 2 and 3 antibody responses were observed in 7/9 patients. Among them, positive conversions to T helper 2 (Th2)-type antibody responses (IgG4 and IgE) were observed after frequent vaccination in 4/7 patients. The Th2 conversion was possibly associated with undesirable clinical observations, including progressive disease and the appearance of a new relapse lesion. The present study suggested that frequent vaccinations activated a Th2-dominant status in the cancer patients. The identification of a time-dependent IgG subclass and IgE antibody production during vaccination protocols may be a useful surrogate marker indicating a potentially undesirable change of the immunological environment for an effective antitumor immune response in cancer patients.
資料タイプ: article
URI: http://hdl.handle.net/2115/64709
出現コレクション:雑誌発表論文等 (Peer-reviewed Journal Articles, etc)

提供者: 京極 典憲

 

本サイトに関するご意見・お問い合わせは repo at lib.hokudai.ac.jp へお願いします。 - 北海道大学